drugset / Trial / NCT01105793

An Open-Label, MultiCenter Evaluation of the Use of Topically Administered FP1198 in Subjects With Pain Associated With Cyclic Mastalgia

NCT01105793

Phase 2 Completed 20 enrolled FemmePharma Global Healthcare, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety of topical FP1198 for the treatment of moderate to severe cyclic breast pain (cyclic mastalgia) and to examine the clinical activity of FP1198.

Timeline

Start
2010-06
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Danazol Other / unclassified Topical